Immix Biopharma (IMMX)

Company Profile

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy (“CAR-T”) in light chain (AL) Amyloidosis and autoimmune disease. Our lead cell therapy candidate is U.S. Food and Drug Administration (“FDA”) investigational new drug (“IND”) cleared CAR-T NXC-201, currently being evaluated in our ongoing Phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. Based on early clinical data, we believe NXC-201 has the potential to be the world’s first “Single-Day Cytokine Release Syndrome”, or “Single-Day CRS” CAR-T (CRS median onset day 1, median duration 1 day), enabling the potential for a faster return home for patients. NXC-201 has been awarded Orphan Drug Designation (“ODD”) by the FDA in both AL Amyloidosis and multiple myeloma, and ODD by the European Commission (“EMA”) in AL Amyloidosis.

Company profile

Ticker

IMMX

Exchange

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology (except Nanobiotechnology)

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • AbbVie • Bausch Health Companies • Celgene ...

SEC CIK

0001873835

Corporate docs

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Immix Biopharma Australia Pty Ltd. • Nexcella, Inc. ...

IRS number

454869378

IMMX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

12 Aug 24

California Institute for Regenerative Medicine Awards Funding for

26 Jul 24

8-K

Changes in Registrant's Certifying Accountant

19 Jul 24

S-8

Registration of securities for employees

19 Jul 24

8-K

Departure of Directors or Certain Officers

14 Jun 24

DEFA14A

Additional proxy soliciting materials

21 May 24

8-K

Unregistered Sales of Equity Securities

20 May 24

Indefinite amount in equity, 14 investors

9 May 24

Latest ownership filings

View all

Yekaterina Chudnovsky

Financial summary

Financial statements Chart IMMX financial data

Quarter (USD)	Jun 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	23.98 mm	23.98 mm	23.98 mm	23.98 mm	23.98 mm	23.98 mm
Cash burn (monthly)	1.78 mm	(no burn)	1.57 mm	1.68 mm	1.75 mm	1.24 mm
Cash used (since last report)	4.07 mm	n/a	3.58 mm	3.85 mm	4.00 mm	2.83 mm
Cash remaining	19.90 mm	n/a	20.39 mm	20.13 mm	19.97 mm	21.15 mm
Runway (months of cash)	11.2	n/a	13.0	12.0	11.4	17.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2024

IMMX institutional ownership history Ownership history

17.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	7	1	+600.0%
Opened positions	6	0	NEW
Closed positions	0	16	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	514.27 mm	6.41 mm	+7918.0%
Total shares	4.87 mm	3.26 mm	+49.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
GKCC	3.26 mm	$6.41 mm	0.0%
Hirschman Orin	1.46 mm	$4.12 mm	NEW
Private Advisor	98.78 k	$303.24 mm	NEW
Commonwealth Equity Services	26.08 k	$80.00 k	NEW
Tritonpoint Wealth	24.53 k	$169.72 mm	NEW
ONB Old National Bancorp	10.00 k	$30.70 mm	NEW
Simplex Trading	509.00	$1.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Hirschman Orin	1.46 mm	+1.46 mm	NEW
Private Advisor	98.78 k	+98.78 k	NEW
Commonwealth Equity Services	26.08 k	+26.08 k	NEW
Tritonpoint Wealth	24.53 k	+24.53 k	NEW
ONB Old National Bancorp	10.00 k	+10.00 k	NEW
Simplex Trading	509.00	+509.00	NEW
GKCC	3.26 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IMMX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Aug 24	Jason Hsu	Common Stock	Buy	Acquire P	No	No	2.251	8,100	18.23 k	845,300
21 Aug 24	Jason Hsu	Common Stock	Buy	Acquire P	No	No	2.226	15,000	33.39 k	837,200
16 Aug 24	Carey Ng	Common Stock	Buy	Acquire P	No	No	1.86	10,000	18.60 k	20,000
24 Jul 24	Jason Hsu	Common Stock	Buy	Acquire P	No	No	2.1462	6,000	12.88 k	822,200
18 Jul 24	Jason Hsu	Common Stock	Buy	Acquire P	No	No	2.0748	3,200	6.64 k	816,200
11 Jun 24	Marquet Magda	Stock Option Common Stock	Grant	Acquire A	No	No	2.04	33,000	67.32 k	33,000
11 Jun 24	Yekaterina Chudnovsky	Stock Option Common Stock	Grant	Acquire A	No	No	2.04	33,000	67.32 k	33,000